CL2021002390A1 - Derivados de pirimidona de anillo fusionado para su uso en el tratamiento de la infección por vhb (virus hepatitis b) o de enfermedades inducidas por el vhb. - Google Patents

Derivados de pirimidona de anillo fusionado para su uso en el tratamiento de la infección por vhb (virus hepatitis b) o de enfermedades inducidas por el vhb.

Info

Publication number
CL2021002390A1
CL2021002390A1 CL2021002390A CL2021002390A CL2021002390A1 CL 2021002390 A1 CL2021002390 A1 CL 2021002390A1 CL 2021002390 A CL2021002390 A CL 2021002390A CL 2021002390 A CL2021002390 A CL 2021002390A CL 2021002390 A1 CL2021002390 A1 CL 2021002390A1
Authority
CL
Chile
Prior art keywords
hvb
hepatitis
virus
treatment
infection
Prior art date
Application number
CL2021002390A
Other languages
English (en)
Inventor
Koen Vandyck
Stefaan Julien Last
Wim Gaston Verschueren
Pierre Jean-Marie Bernard Raboisson
Bart Rudolf Romanie Kesteleyn
Tim Hugo Maria Jonckers
Sandrine Céline Grosse
Jan Martin Berke
Meng-Yang Hsiao
Lili Hu
Edgar Jacoby
Lamenca Carolina Martinez
Mathieu Perrier
Serge Maria Aloysius Pieters
Abdellah Tahri
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of CL2021002390A1 publication Critical patent/CL2021002390A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente solicitud se refiere a compuestos de acuerdo con la fórmula (I), composiciones farmacéuticas que comprenden al menos uno de dichos compuestos, su uso como medicamento y su uso en el tratamiento de la infección crónica por el virus de la hepatitis B (VHB). La divulgación se refiere además a métodos para preparar compuestos de acuerdo con la fórmula (I).
CL2021002390A 2019-03-14 2021-09-13 Derivados de pirimidona de anillo fusionado para su uso en el tratamiento de la infección por vhb (virus hepatitis b) o de enfermedades inducidas por el vhb. CL2021002390A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19162954 2019-03-14

Publications (1)

Publication Number Publication Date
CL2021002390A1 true CL2021002390A1 (es) 2022-04-22

Family

ID=65817822

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002390A CL2021002390A1 (es) 2019-03-14 2021-09-13 Derivados de pirimidona de anillo fusionado para su uso en el tratamiento de la infección por vhb (virus hepatitis b) o de enfermedades inducidas por el vhb.

Country Status (23)

Country Link
US (1) US20230091047A1 (es)
EP (1) EP3938362A1 (es)
JP (1) JP2022524456A (es)
KR (1) KR20210139319A (es)
CN (1) CN113710667A (es)
AR (1) AR118358A1 (es)
AU (1) AU2020235270A1 (es)
BR (1) BR112021017415A2 (es)
CA (1) CA3132531A1 (es)
CL (1) CL2021002390A1 (es)
CO (1) CO2021011295A2 (es)
CR (1) CR20210482A (es)
DO (1) DOP2021000185A (es)
EA (1) EA202192512A1 (es)
EC (1) ECSP21067189A (es)
IL (1) IL286210A (es)
JO (1) JOP20210249A1 (es)
MA (1) MA55286A (es)
MX (1) MX2021011107A (es)
PE (1) PE20212325A1 (es)
SG (1) SG11202109575UA (es)
TW (1) TW202100524A (es)
WO (1) WO2020182990A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022053010A1 (en) * 2020-09-11 2022-03-17 Janssen Sciences Ireland Unlimited Company Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases
JP2023548031A (ja) * 2020-10-21 2023-11-15 アリゴス セラピューティクス インコーポレイテッド 二環式化合物
US11957683B2 (en) 2021-06-18 2024-04-16 Aligos Therapeutics, Inc. Bicyclic compounds
WO2023205653A1 (en) * 2022-04-20 2023-10-26 Aligos Therapeutics, Inc. Bicyclic compounds
WO2023205645A1 (en) * 2022-04-20 2023-10-26 Aligos Therapeutics, Inc. Bicyclic compounds
WO2024015425A1 (en) 2022-07-14 2024-01-18 Fmc Corporation Herbicidal benzoxazines
WO2024073559A1 (en) * 2022-09-30 2024-04-04 Aligos Therapeutics, Inc. Bicyclic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008038768A1 (fr) * 2006-09-28 2008-04-03 Dainippon Sumitomo Pharma Co., Ltd. Composé ayant une structure de pyrimidine bicyclique et composition pharmaceutique comprenant le composé
WO2008130581A1 (en) 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
CN101854597B (zh) 2009-04-03 2015-06-03 中兴通讯股份有限公司 大消息模式融合ip消息传输方法及系统
WO2011111880A1 (ko) * 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
JP2012126698A (ja) * 2010-12-17 2012-07-05 Tsutomu Takeuchi テトラヒドロピリドピリミジン誘導体を有効成分とするｂａｆｆの結合阻害剤
WO2016109684A2 (en) * 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
EP3535261B1 (en) * 2016-11-03 2020-08-05 F. Hoffmann-La Roche AG Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Also Published As

Publication number Publication date
TW202100524A (zh) 2021-01-01
IL286210A (en) 2021-10-31
KR20210139319A (ko) 2021-11-22
US20230091047A1 (en) 2023-03-23
CA3132531A1 (en) 2020-09-17
JP2022524456A (ja) 2022-05-02
AR118358A1 (es) 2021-09-29
EA202192512A1 (ru) 2022-02-16
MX2021011107A (es) 2022-01-19
MA55286A (fr) 2022-01-19
EP3938362A1 (en) 2022-01-19
PE20212325A1 (es) 2021-12-14
SG11202109575UA (en) 2021-09-29
BR112021017415A2 (pt) 2022-02-01
CR20210482A (es) 2021-11-09
JOP20210249A1 (ar) 2023-01-30
DOP2021000185A (es) 2022-01-16
AU2020235270A1 (en) 2021-08-12
CO2021011295A2 (es) 2021-09-20
CN113710667A (zh) 2021-11-26
ECSP21067189A (es) 2021-11-18
WO2020182990A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
CL2021002390A1 (es) Derivados de pirimidona de anillo fusionado para su uso en el tratamiento de la infección por vhb (virus hepatitis b) o de enfermedades inducidas por el vhb.
BR112018075465A2 (pt) agentes antivirais de hepatite b
BR112018067964A2 (pt) agentes antivirais para hepatite b
EA201891876A1 (ru) Тетрациклические пиридоновые соединения в качестве противовирусных средств
UY38483A (es) Heterociclos funcionalizados como agentes antivirales
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
BR112015024552A2 (pt) compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções
BR112017011941A2 (pt) compostos 5-amino-6h-tiazol [4,5-d] pirimidina-2,7-diona substituídos 3 para o tratamento e profilaxia de infecção viral
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
CL2016002179A1 (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b.
UY38059A (es) Heterociclos sustituidos como agentes antivirales
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
CL2015001304A1 (es) Compuestos derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
CL2008002995A1 (es) Compuestos derivados de espiropirrolidina; composicion farmaceutica que los comprende; procedimiento de preparacion de compuestos intermediarios; y su uso para tratar la infeccion del virus de la hepatitis c y del vih.
ECSP15035530A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
BR112014019584A8 (pt) Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
CL2015001319A1 (es) Compuestos derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
BR112019005205A2 (pt) composto de di-hidropirimidina e método de preparação e uso do mesmo
BR112021022889A2 (pt) Derivados heterocíclicos fundidos
BR112014015582A2 (pt) compostos antivirais
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
CL2017001161A1 (es) Composiciones farmacéuticas de acción prolongada para la hepatitis c
CL2017001160A1 (es) Combinación de composiciones de acción prolongada y métodos para la hepatitis c